Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T-cell sensitivity to glucocorticoid during HTLV-I-induced transformation by Chen, Z et al.
ORIGINAL ARTICLE
Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T-cell sensitivity
to glucocorticoid during HTLV-I-induced transformation
Z Chen
1, DA Lopez-Ramos
1,2, E Yoshihara
1,2, Y Maeda
3, H Masutani
1, K Sugie
1, M Maeda
1 and J Yodoi
1
1Laboratory of Infection and Prevention, Department of Biological Response, Institute for Virus Research, Kyoto University,
Kyoto, Japan;
2Division of Systemic Life Science, Graduate School of Biostudies, Kyoto University, Kyoto, Japan and
3Department of Hematology, Kinki University School of Medicine, Osaka, Japan
Although glucocorticoid (GC) is widely used for treating hema-
topoietic malignancies including adult T-cell leukemia (ATL),
the mechanism by which leukemic cells become resistant to GC
in the clinical course remains unclear. Using a series of T-cell
lines infected with human T lymphotropic virus type-I (HTLV-I),
the causative virus of ATL, we have dissected the transforma-
tion from interleukin (IL)-2-dependent to -independent growth
stage. The transformation associates the loss of thioredoxin-
binding protein-2 (TBP-2), a tumor suppressor and regulator of
lipid metabolism. Here we show that TBP-2 is responsible for
GC-induced apoptosis in ATL cells. In the IL-2-dependent stage,
dexamethasone induced TBP-2 expression and apoptosis, both
of which were blocked by GC receptor (GR) antagonist RU486.
Knockdown of TBP-2 consistently reduced the amount of
GC-induced apoptosis. In IL-2-independent stage, however,
expression of GR and TBP-2 was suppressed and GC failed to
induce apoptosis. Forced expression of GR led the cells to mild
sensitivity to GC, which was also accomplished by treatment
with suberoylanilide hydroxamic acid, a TBP-2 inducer. A
transfection experiment showed that TBP-2 expression induced
apoptosis in IL-2-independent ATL cells. Thus, TBP-2 is likely
to be one of the key molecules for GC-induced apoptosis and a
potential target for treating the advanced stage of ATL.
Leukemia (2011) 25, 440–448; doi:10.1038/leu.2010.286;
published online 10 December 2010
Keywords: HTLV-I; ATL; glucocorticoid receptor; glucocorticoid;
thioredoxin-binding protein-2/thioredoxin-interacting protein;
apoptosis
Introduction
Since the ﬁrst reports of adult T-cell leukemia (ATL) in the
1970s,
1,2 decades of studies have focused on this hematological
malignancy because of its unique late-onset clinical manifesta-
tions, the dysregulation of the interleukin 2 (IL-2) receptor
and the causative agent, human T-cell leukemia virus type I
(HTLV-I).
3–5 The pathogenesis of ATL is a multistep process
because overt leukemia develops in some HTLV-I carriers after a
long latent period.
6 It is thought that in the initial stage of
leukemogenesis, HTLV-I-infected CD4
þ T cells grow on the
condition that IL-2 is available, whereas in the terminal and
acute stage of ATL, these cells expand independently of growth
factors in vivo.
7,8 Many HTLV-I-infected T-cell lines derived
from ATL patients need to be maintained initially in the
presence of IL-2 (IL-2-dependent growth stage (D stage)),
although the same cell lines spontaneously acquire indepen-
dence of exogenous IL-2 supplementation later during the
long-term culture (IL-2-independent growth stage (I stage)). On
the basis of the parallelism between in vivo and in vitro growth
of ATL cells, the in vitro transition from IL-2-dependent
to -independent growth has been a useful model for investigat-
ing the mechanism by which ATL develops in vivo, as well as for
exploring possible strategies to treat this leukemia.
9–11
Glucocorticoid (GC) has been included in the standard
therapy of hematological malignancies.
12,13 However, GC is
of limited use in the treatment of ATL owing to the frequent
occurrence of GC resistance and exacerbation of the immuno-
suppressive status inherently associated with this leukemia.
14
The mechanism for the lack of GC efﬁcacy seen in ATL cases
remains unclear. GC receptor (GR), represented by the
functional a isoform (GRa), mediates most of the pleiotropic
GC activities. Upon ligand binding, GR translocates from the
cytoplasm to the nucleus and regulates the expression of target
genes through trans-activation or trans-repression mechan-
ism.
15,16 Extensive studies have been conducted to clarify the
mechanism by which HTLV-I affects GR signaling, revealing
that the oncoprotein Tax1 encoded by HTLV-I plays a critical
role in repressing nuclear receptor-dependent transcription.
17,18
Tax1 also affects nuclear factor-kB and signal transducer and
activator of transcription 5 signaling, both of which are major
downstream targets of GR signaling.
19,20 Taken together, there is
a unique alteration in the responsiveness to GC in ATL.
Thioredoxin is a 12-kDa protein that harbors the CXXC motif
and plays a critical role in redox regulation. After reporting that
thioredoxin was expressed in ATL cells at an extremely high
level,
21 our studies have focused on the role of thioredoxin
in the leukemogenesis by HTLV-I. A yeast two-hybrid
assay allowed us to identify thioredoxin-binding protein-2
(TBP-2/VDUP-1/TXNIP) as an endogenous binding partner and
antagonist of thioredoxin.
22 Thioredoxin and TBP-2 are involved
in the ASK1-dependent apoptosis pathway.
23,24 Blocking
thioredoxin of cancer cells was suggested to be a useful
approach to cancer therapy.
25,26 TBP-2 is induced by GC in
murine normal thymocytes and the T-cell lymphoma line
WEHI7.2.
27 Intriguingly, TBP-2 expression is lost during the
progression of HTLV-I-induced transformation.
28,29 On the basis
of these observations, we hypothesized that TBP-2 plays a
critical role in GC-induced ATL cell death. If this is the case, it is
possible that the diversity in the GC efﬁcacy in treating ATL
patients is explained by the expression of TBP-2.
In this study, we used a series of HTLV-I-infected T-cell lines
independently established from ATL patients and found that
the GR–TBP-2 signaling axis plays a key role in mediating
GC-induced cell death.
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Cell culture
HTLV-I-infected human T-cell lines (ED40515, ATL43, ATL2
and Sez627) were cultured in RPMI 1640 medium (Sigma-
Aldrich, St Louis, MO, USA) containing 10% heat-inactivated
fetal calf serum (Invitrogen, Carlsbad, CA, USA) and antibiotics
(100U/ml penicillin and 100mg/ml streptomycin; Nacalai
Tesque, Kyoto, Japan) at 371C in a humid atmosphere of 5%
CO2 in air. To maintain the growth of the IL-2-dependent T cells,
recombinant human IL-2 (7.5ng/ml; Shionogi Co., Osaka,
Japan) was added to the culture medium. Each set of
IL-2-dependent and -independent cells had the same clonal
origin as conﬁrmed by the T-cell receptor-b gene rearrangement
and the HTLV-I proviral integration sites.
9–11 D-ED40515,
D-ATL43, D-Sez627 or D-ATL2T cell lines are IL-2-dependent
HTLV-I-transformed T cells that grew solely in the presence of
IL-2, whereas I-ED40515, I-ATL43, I-Sez627 or I-ATL2T cell
lines are IL-2-independent derivatives of the above cells that
grew independent of IL-2. Exogenous IL-2 is indispensable for
the continued cell expansion in the D stage. In I stage, however,
exogenous IL-2 is no longer required for maintaining cell
growth, and neither is cell growth affected by IL-2 supplementa-
tion (data not shown).
Plasmids
The full-length cDNA of human GRa was cloned in-frame into
the pCMV-tag3B vector (Stratagene, La Jolla, CA, USA). Brieﬂy,
the cDNA was ﬁrst ampliﬁed by PCR using primers (forward:
50-GGATCCATGGACTCCAAAGAATCATT-30 and reverse:
50-CTCGAGTCACTTTTGATGAAACAGAAG-30). The PCR pro-
duct was then subcloned into pCR-BluntII-TOPO vector (Invitro-
gen) to obtain pCR-BluntII-TOPO-GR, which was further digested
with BamHI and XhoI restriction enzymes (Toyobo, Tokyo, Japan).
The fragment was ﬁnally cloned into the pCMV-tag3B vector to
obtain the pCMV-tag3B-GRa plasmid. With regard to the pCMV-
tag2A-TBP-2, full-length cDNA of human TBP-2 was cloned
in-frame into the pCMV-tag2A vector (Stratagene), as described
previously.
28 Each plasmid was veriﬁed by DNA sequencing.
Transient transfection and RNA interference assay
Plasmids were transfected into cells (1 10
6 cells) using the
Nucleofector II and AMAXA cell line kit V (Lonza Cologne,
Cologne, Germany), according to the manufacturer’s instruc-
tions. Unless otherwise mentioned, 5mg of DNA was used for
each transfection. Expression of the target protein was veriﬁed
by western blotting. In RNAi assays, we employed 100pmol
of duplex oligonucleotides selectively silencing the TBP-2
(RNA interference (RNAi) no. 1: UUUCAGGGUCGUUAAAGA
CCACCUC; RNAi no. 2: UCAAUUCGAGCAGAGACAGACAC
CC or RNAi no. 3: AUCCAAAGCACUUUAGCCACUCCGC)
(Invitrogen) or control oligonucleotides (Stealth RNAi-negative
control) (Invitrogen). siRNAs were transfected into cells (1 10
6
cells) using the Nucleofector II and AMAXA cell line kit V. IL-2
was added at 7.5ng/ml at least 24h after the transfection to
maintain the growth of D-ED40515 and D-ATL43 cells.
29
Treatment of ATL cells with GC or other reagents
IL-2-dependent HTLV-I-infected T cells were ﬁrst deprived
of IL-2 for at least 24h to exclude the carry-over effect of
IL-2 on cell growth. Then, viable cells were enriched using
LSM Lymphocyte Separation Medium according to the
manufacturer’s instruction (MP Biomedicals, Aurora, OH,
USA). Dexamethasone (Dex) (Nacalai Tesque) or GC antagonist
RU486 (Sigma-Aldrich, San Diego, CA, USA) was added to the
culture medium, whereas ethanol (0.004% v/v) was added as a
vehicle control. In experiments using IL-2-independent HTLV-I-
infected cells, Dex or suberoylanilide hydroxamic acid (SAHA)
(Qbiogene, San Diego, CA, USA) was added directly to the cells.
RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted using TRIzol reagent according to the
manufacturer’s instructions (Invitrogen). Total RNA (1mg) was
used as a template for the cDNA synthesis using the PrimeScript
RT reagent kit according to the manufacturer’s instruction
(Takara, Otsu, Japan). A 1:20 fraction of each reverse
transcriptase reaction mixture was further used as a template
for real-time quantitative PCR using the SYBR Premix TaqII kit
(Takara) with TBP-2 primers (forward: 50-GCCACACTTACCTT
GCCAAT-30 and reverse: 50-GGAGGAGCTTCTGGGGTATC-30),
GR-a-speciﬁc primers (forward: 50-CCATTGTCAAGAGGGAA
GGA-30 and reverse: 50-CAGCTAACATCTCGGGGAAT-30)o r
glyceraldehyde 3-phosphate dehydrogenase primers (forward:
50-ACCCACTCCTCCACCTTTG-30 and reverse: 50-CTCTTGTGC
TCTTGCTGGG-30). Fluorescent detection and data analysis
were performed on an ABI Prism 7000 Sequence Detection
System (Applied Biosystems, Foster City, CA, USA).
Immunoblotting
Cells were washed twice in cold phosphate-buffered saline and
resuspended in lysis buffer (0.5% NP-40, 50mM Tris-Cl (pH
7.2), 150mM NaCl) supplemented with 1  protease inhibitor
cocktail (Roche, Tokyo, Japan) and 1mM phenylmethylsulfonyl
ﬂuoride (Nacalai Tesque). The cell lysates were fractionated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
using 4–12% NuPage Bis–Tris pre-cast gel (Invitrogen)
and transferred to a polyvinylidene ﬂuoride membrane (GE
Lifesciences, Pittsburgh, PA, USA). The membranes were ﬁrst
incubated with anti-TBP-2 antibody (JY2, 1:1000; MBL, Nagoya,
Japan), anti-GR-a (P-20, 1:200; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), anti-b-actin (1:2000; Sigma-Aldrich or
sc-81178, 1:200; Santa Cruz), anti-cleaved caspase-3 (1:1000;
Cell Signaling, Danvers, MA, USA), anti-poly (ADP-ribose)
polymerase (PARP) (1:1000; Cell Signaling), anti-Flag (1:2000;
Sigma-Aldrich) or anti-myc (9E10, 1:200; Santa Cruz), washed
and incubated with horse radish peroxidase-conjugated
secondary anti-mouse-immunoglobulin G or anti-rabbit-immu-
noglobulin G (GE Lifesciences). Washing and incubation were
performed using SNAP i.d. Protein Detection System (Millipore,
Billerica, MA, USA). Finally, chemiluminescence was detected
using Chemi-Lumi One L kit (Nacalai Tesque). For densitometry
analysis, luminescence images were analyzed by the ImageJ
software (NIH, Bethesda, MD, USA).
Flow cytometry
Cells were washed twice in phosphate-buffered saline and
resuspended in 1  Annexin V binding buffer (BD Pharmingen,
San Diego, CA, USA). For apoptosis analysis, cells were
immediately stained using an Annexin V-FITC apoptosis
detection kit (BD Pharmingen) and analyzed using a BD
FACSCanto II Flow Cytometry System (BD Biosciences, San
Jose, CA, USA). Cell debris was ﬁrst excluded by gating on the
forward and the side scatters. The annexin V-positive and
propidium iodide-negative quadrant represents the population
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Data were analyzed using the FlowJo software (Treestar,
Ashland, OR, USA).
Cell proliferation assay
Cells (0.5–1 10
4 cells) were seeded in 96-well ﬂat-bottom
microtiter culture plates with low evaporation lids (Corning Inc.,
Figure 1 Dexamethasone inhibits cell growth in the early, but not the late stage of HTLV-I-induced transformation. IL-2-dependent HTLV-I-
infected T cells (D-ED40515, D-ATL43, D-ATL2T cells), representing the early transformation, and their IL-2-independent derivatives (I-ED40515,
I-ATL43, I-ATL2T cells), representing the late stage of transformation, were treated with Dex or ethyl alcohol. (a) Cell proliferations of D-ED40515/
I-ED40515T cells were examined by SF cell count reagent at 72h after treatments. Data were shown as mean±s.d. (n¼6). *Po0.05; **Po0.01;
***Po0.001. (b) At 48h after Dex treatment, D-ED40515T cells were collected and used for immunoblotting to detect cleaved caspase-3 and
PARP. b-Actin served as a loading control. Uncl, uncleaved; cl, cleaved. (c) At 48h of culture, D-ED40515 (upper panel) and I-ED40515 (lower
panel) T cells were collected and used for ﬂow cytometry to assess the proportion of early apoptosis. Data are expressed as mean±s.d. (n¼3).
(d and e) At 48h after Dex treatment, I-ED40515T cells were collected and immunoblotting and ﬂow cytometry were carried out, respectively,
as in (b) and (c). (f) Cell proliferations of D-ATL43/I-ATL43T cells were as in (a). (g–j) D-ATL43/I-ATL43 cells after Dex treatment were used for
immunoblotting and ﬂow cytometry analysis as in (b–d). (k) Cell proliferations of D-ATL2/I-ATL2T cells were as in (a). (l–o) D-ATL2/I-ATL2 cells
after Dex treatment were used for immunoblotting and ﬂow cytometry analysis as in (b–d).
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count reagent according to the manufacturer’s instruction
(Nacalai Tesque). The optical density value after the addition
of SF reagent was measured using a Microplate Reader
(Molecular Devices, Sunnyvale, CA, USA) at optical density
450–650nm wavelengths. The mean optical density value of
control group was arbitrarily set to 100%.
Statistical analysis
Data are expressed as mean±s.d. Statistical analysis
was performed using the unpaired Student’s t-test
(two tailed). Results were considered statistically signiﬁcant
when Po0.05.
Results
Loss of GC sensitivity during transformation of
HTLV-I-infected T cells
HTLV-I-infected T cells tend to undergo a transition from
D stage to I stage. On the other hand, ATL has been postulated
to develop in vivo in a multistep manner.
6 Several lines of
evidence have indicated that the D stage cells represent the
early transformed leukemic cells, whereas the I stage cells
represent the fully transformed leukemic cells.
8,30 To investigate
the responsiveness of ATL cells to GC, we took advantage of
HTLV-I-infected T-cell lines (ED40515, ATL43 or ATL2)
established from three distinct ATL patients. The IL-2-dependent
lines (D-ED40515, D-ATL43 or D-ATL2T cells) sponta-
neously gave rise to subclones that grew in the absence of
IL-2 (I-ED40515, I-ATL43 or I-ATL2T cells, respectively)
(Supplementary Figure S1).
11 Dex inhibited the growth of IL-2-
dependent cells, but not of IL-2-independent cells in all three
cell lines examined (Figures 1a, f and k and Supplementary
Figure S2). We next addressed apoptosis induced by Dex. In the
IL-2-dependent cells, Dex increased the active form (p17)
of caspase 3 (Figures 1b, g and l, upper) and the cleaved form of
its target, nuclear PARP (Figures 1b, g and l, middle) in a dose-
dependent manner. In contrast, IL-2-independent T cells did not
respond to Dex in caspase activation (Figures 1d, i and n).
Consistently, Dex increased the early apoptotic population in
the D stage (Figures 1c, h and m), but not in the I stage cells
(Figures 1e, j and o) as revealed by ﬂow cytometry.
GR and TBP-2 expression are diminished during
transformation of HTLV-I-infected T cells
To dissect the mechanism of the differential sensitivities to Dex
seen during the transformation of HTLV-I-infected T cells, we
examined the expression of GR. Quantitative real-time PCR
(qRT-PCR) revealed that I-ED40515 cells expressed approxi-
mately one-eighth as much the functional isoform of GR (GRa)
as D-ED40515 cells (Figure 2a). Likewise, three other pairs of I
and D stage T-cell lines showed a tendency of losing GRa
expression when they proceeded from the early to the late phase
of transformation. Consistent with our previous ﬁndings,
28,29
the expression of TBP-2 declined when HTLV-I-infected T cells
went through the transition (Figure 2b). Of note, the decline
of TBP-2 mRNA was more pronounced than that of GR in
the course of the transition. In line with the mRNA levels,
immunoblotting indicates that the protein amounts of GRa and,
more markedly, those of TBP-2 diminished in the
transition from the D stage to I stage of HTLV-I-infected T cells
(Figure 2c).
GR mediates upregulation of TBP-2, growth arrest and
apoptosis induced by GC in the early stage of
transformation by HTLV-I
Dex induced TBP-2 mRNA and protein in a dose-dependent
manner in the D-ED40515, D-ATL43 or D-ATL2T cells (Figures
3a and g and Supplementary Figure S3), whereas it failed to do
so in the I-ED40515, I-ATL43 or I-ATL2T cells (Figures 3b and h
and Supplementary Figure S3). To determine whether TBP-2 is
involved in the signals downstream of GR in the D stage of
T cells, we included a GR antagonist (RU486) in the culture.
RU486 abolished growth inhibition, early apoptosis and caspase
activation induced by Dex in D-ED40515 (Figures 3c, d, and e)
or D-ATL43 T cells (Figures 3i, j and k). RU486 also abrogated
Figure 2 Expression of GR and TBP-2 was diminished during HTLV-I-
induced transformation. The amounts of GRa (a) and TBP-2 mRNA
(b) were determined by real-time quantitative RT-PCR. The relative
mRNA expressions normalized to the glyceraldehyde 3-phosphate
dehydrogenase expressions are shown and expressed as mean±s.d.
(n¼3). *Po0.05; **Po0.01. (c) Immunoblotting was performed to
detect GRa and TBP-2 proteins. b-Actin served as a loading control.
Representative results of three independent experiments were shown.
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(Figures 3f and l). These data indicate that the signal through GR
upregulates TBP-2 in the D stage of HTLV-I-infected cells, but
not in the I stage of the cells. Furthermore, the expression levels
of TBP-2 paralleled GR-mediated growth inhibition, cell death
and caspase activation.
Knockdown of TBP-2 in the early stage of HTLV-I-
induced transformation abrogates GC effects
As TBP-2 can mediate apoptosis in several cell types,
31,32 we
hypothesized that this protein plays an important role when GC
inhibits the expansion of the D stage of ATL cells. To test this, we
performed an RNAi assay to reduce the expression of TBP-2 in
D-ED40515 and D-ATL43 cells. We transfected the cells with
siRNA, treated them with Dex for 24h and determined cell
growth and apoptosis. Two independent sets of siRNA speciﬁc
for TBP-2 likewise diminished the protein expression by more
than 80%, compared with scrambled control siRNA in both of
the D stage T cells (Figures 4a and c). Gene silencing of TBP-2
abolished apoptosis induced by Dex (Figures 4b and d). These
data indicate that TBP-2 is an essential intermediate for cell
death induced by GC in the early stage of T-cell transformation.
Forced expression of GR and treatment with SAHA in
the late stage of HTLV-I-induced transformation restores
GC sensitivity
One possible strategy to control the growth of advanced ATL
cells is to restore the responsiveness to GC. To test this in vitro,
we used I-ED40515T cells. As these I stage T cells lacked the
expression of both GR and TBP-2, we replenished the cells with
the expression of either or both of the molecules and tested
whether they were rendered responsive to GC. I-ED40515T cells
were transfected with a high dose of GRa-encoding plasmids
(Figure 5a). Transfection with GRa partially rendered the cells
responsive to Dex and induced a moderate activation of caspase
3 as determined by the cleavage of PARP (Figures 5b, compare
lanes 5 and 6) and early apoptosis (Figure 5c, compare columns
5 and 6). Furthermore, the cells transfected with a high-dose
GRa-encoding plasmid slightly increased the expression of
TBP-2 in response to Dex (Figure 5d, column 6).
SAHA, an inhibitor for histone deacetylase, strongly enhances
the expression of mutiple genes including TBP-2.
33 Unexpect-
edly, treatment with SAHA in the absence of Dex robustly
induced TBP-2 mRNA in myc-GR transfectants (Figure 5d,
column 7), but not in the control transfectants (Figure 5d,
column 3). The treatment with SAHA alone also induced
caspase activation (Figure 5b, lane 7) and early apoptosis
(Figure 5c, column 7) only in myc-GR transfectants.
Figure 3 GR mediates TBP-2 induction, apoptosis and caspase
activation in the early stage of HTLV-I-induced transformation. (a)A t
48h after treatment with doses of Dex, D-ED40515T cells were collected.
TBP-2 mRNA levels were measured by quantitative RT-PCR (upper
panel). Data are shown as mean±s.d. (n¼4). ***Po0.001. Immuno-
blotting was also performed to detect TBP-2 protein (lower panel). b-Actin
served as a loading control. (b) At 48h after treatment with doses of Dex,
I-ED40515T cells were collected. TBP-2 mRNA (upper panel) and protein
(lower panel) were measured as in (a). The ‘0’ indicated no detection
within the PCR cycles (n¼40). (c–f) D-ED40515T cells were treated,
respectively, with either 10nM Dex or 100nM RU486, or both, for 48h.
Samples treated with ethanol vehicle (0.004%, v/v) were used as a
negative control. (c) Cell growth was examined using SF cell count
reagent. (d) Early apoptosis was determined by ﬂow cytometry.
(e) Immunoblotting was performed to detect cleaved caspase-3 and
PARP. Uncl, uncleaved; cl, cleaved. (f) TBP-2 mRNA (upper panel) and
protein (lower panel) were measured by real-time quantitative RT-PCR
and immunoblotting, respectively. **Po0.01. Representative results
of three independent experiments were shown. (g–l) ATL43T cells
(D-ATL43/I-ATL43) were used as in (a–f).
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cell death or TBP-2 expression as compared with SAHA alone in
either myc-GR or control transfectants. Collectively, induction
of TBP-2 in the I stage T cells by various reagents associated with
caspase activation and enhancement of early apoptosis.
To address the role of TBP-2 in GR-mediated apoptosis, TBP-2
expression was diminished by TBP-2 siRNA in I-ED40515 cells
transfected with myc-GR and treated with SAHA and Dex.
The knockdown modestly but signiﬁcantly reduced both TBP-2
mRNA (Figure 5e) and apoptosis (Figure 5f). These results
suggest that TBP-2 expression is a crucial step in GR-mediated
apoptosis in HTLV-I-transformed cells.
Ectopic expression of TBP-2 alone induces cell death in
the late stage of HTLV-I-transformation
Although SAHA strongly enhanced the effect of Dex on growth
suppression and caspase activation, this reagent could affect
expression of other molecules than TBP-2.
33 Therefore, we
determined whether direct expression of TBP-2 in the advanced
stage of HTLV-I-infected cells regulates cell growth and
apoptosis. We transfected I-ED40515T cells (Figure 6a) and
I-ATL43T cells (Figure 6b) with TBP-2 and determined cell
death. The expression of TBP-2 alone signiﬁcantly increased
active caspase-3 and cleavage of PARP with enhanced apoptosis
48h after the transfection regardless of GC treatment
(Supplementary Figure S4). These data indicate that TBP-2,
when expressed in the late stage of HTLV-I-infected T-cell line
cells, can control cell growth and apoptosis.
Discussion
After infection with HTLV-I, most patients remain asympto-
matic, although a minority of them go through multistep
tumorigenesis, ending up with acute leukemia resistant to any
therapeutic agents. The in vivo development of aggressive
leukemia is emulated in vitro by the transition of HTLV-I
infected T-cell line cells. In the initial stage of tissue culture,
they grow on the condition of the existence of IL-2 and are
prone to apoptosis upon exposure to GC. As they are kept in
culture for a long time, they start to grow independently of IL-2
and become insensitive to GC. Herein, we show that TBP-2 is
critically involved in the transition of HTLV-I-infected T cells.
The signiﬁcance of TBP-2 in regulating GC-induced growth
suppression and cell death is supported by the following
ﬁndings: (i) knocking down of TBP-2 in the early stage of
HTLV-I-infected T cells rendered them unresponsive to GC and
(ii) forced expression of TBP-2 induced caspase activation and
cell death without engagement of GR.
Cell lines are useful when dissecting molecular mechanisms
of cell growth and death, although there is a caveat that the
experimental results obtained by using cell lines represent
artifact in vitro. Therefore, we used several HTLV-I-infected
T-cell lines that we had established from distinct ATL patients.
All of the cell lines made a transition from the status where they
grow solely in the presence of IL-2 and undergo apoptosis in
response to GC to that in which their growth is independent of
IL-2 and resistant to GC. All cell lines at an early transformation
stage expressed TBP-2, which was further enhanced in response
to GC, although after the transition into the advanced stage
they consistently lost the expression of GR and, more strikingly,
TBP-2. Thus, the ﬁndings in this study suggest the important role
of GR/TBP-2 axis in the apoptosis of leukemic cells in vivo.
Clinical relevance of TBP-2 is currently under investigation. We
collected fresh leukemic cells so far from four ATL patients
that had received chemotherapy including GC (unpublished
observation). Three of them were found to express TBP-2 in their
leukemic cells at the levels as high as normal CD4 cells from
health volunteers and have survived for at least 6 months.
Figure 4 Knockdown of TBP-2 in the early stage of HTLV-I-induced transformation abolishes GC-induced growth inhibition and apoptosis.
(a and b) D-ED40515T cells were transfected with control oligonucleotides (Control RNAi) or two sets of TBP-2 antisense oligonucleotides (RNAi
no. 2, RNAi no. 3) as described in the ‘Materials and methods’ section. At 24h after the transfection, cells were treated with 1mM Dex or the
ethanol (0.1%, v/v) for another 24h. (a) Immunoblotting was performed to detect TBP-2 protein. b-Actin was used as a loading control.
Densitometric ratios of TBP-2/b-actin (T/b) are listed below. ‘þ’, Dex added; ‘ ’, ethanol added. (b) Flow cytometry assay for detecting the early
apoptotic proportion was performed. Data from three independent experiments are shown as mean±s.d., *Po0.05. (c and d) D-ATL43T cells were
used for the TBP-2 knockdown assays as in (a and b).
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expression in the tumor cells turned out to be markedly
suppressed. These results are consistent with the notion that
the loss of TBP-2 expression reﬂects the clinical progression
of ATL.
TBP-2 has been implicated in multiple functions, including
regulation of cell growth, lipid metabolism and non-classical
secretion of cytokines.
34,35 However, the role of this molecule in
mediating GC signaling has not been widely recognized.
Apoptosis assays revealed that T cells puriﬁed from TBP-2-
deﬁcient mice
36 were less sensitive to GC than wild-type T cells
(our unpublished observation), suggesting the physiological
relevance of TBP-2 to GC-induced cell death.
The expression of TBP-2 strikingly declined after HTLV-I-
infected T-cell line cells became IL-2 independent, that is, more
advanced in transformation. Beyond this point, the T cells failed
to express TBP-2 even when they were treated with GC. After
forced expression of GR, SAHA, an inhibitor for histone
Figure 5 Forced expression of GR and treatment with SAHA in the late stage of HTLV-I-induced transformation restores GC sensitivity.
I-ED40515T cells were transfected with 5mg of pCMV-tag3B-GRa or pCMV-tag3B control plasmids. (a) At 24h after transfection, immunoblotting
was performed to verify the expression of GRa.( b–d) Then, ethanol vehicle (0.1%, v/v), dexamethasone (1mM), SAHA (2.5mM) or dexamethasone
(1mM)/SAHA (2.5mM) combinations were added, respectively, into cells. (b) Immunoblotting for PARP was performed. b-Actin was used as a
loading control. Each lane number was labeled below the blot. (c) Cell pellets were collected and ﬂow cytometry analysis was performed. Each
column number was labeled below the graph. (d) Cell pellets were collected to measure TBP-2 mRNA expression by real-time quantitative
RT-PCR. Data of relative TBP-2 expression normalized to the glyceraldehyde 3-phosphate dehydrogenase expression are shown. **Po0.01;
***Po0.001. Each column number was labeled below the graph. (e and f) I-ED40515T cells were transfected with 5mg of pCMV-tag3B-GRa plus
TBP-2 antisense oligonucleotides (RNAi no. 2) or control oligonucleotides. At 24h after transfection, dexamethasone (1mM)/SAHA (2.5mM)
combinations were added into cells. (e) Immunoblotting for myc-tagged GRa and TBP-2 was performed to verify the transfection and knockdown
efﬁciency. ‘þ’, RNAi no. 2 added; ‘ ‘, control RNAi added. Densitometric ratios of TBP-2/b-actin (T/b) are listed below. Representative data
of two independent experiments were shown. (f) Cell pellets were collected and ﬂow cytometry analysis was performed. Data were shown as
mean±s.d. in triplicate.
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Leukemiadeacetylase, strongly induced TBP-2. The mechanism by which
SAHA induced TBP-2 without the addition of Dex remains
unknown. The induction of TBP-2 associated the inhibition of
cell growth and the activation of caspase 3. Furthermore, forced
expression of TBP-2 resulted in caspase activation and cell death
in the advanced stage of HTLV-I-infected T cells. Thus,
enhancement of the expression of TBP-2 in leukemic cells
could provide a promising therapeutic strategy. SAHA is known
to regulate the expression of multiple genes and is currently
widely used in hematological malignancies.
13,33,37 Owing to
the heavy CpG DNA methylation in the advanced stage of
ATL,
29,38 it may be necessary to combine SAHA with other
demethylating agents, including 5-aza-deoxycytidine for better
efﬁcacy. One mechanism of action for these drugs might be the
induction of TBP-2 and restoration of the GR/TBP-2 axis, leading
to enhanced apoptosis of leukemic cells. In addition,
our preliminary analyses with a limited number of ATL
patients suggested the correlation of TBP-2 expression and
prognosis. Although it is obviously necessary to study much
more cases, these ﬁndings suggest that TBP-2 can be a useful
measure to predict the prognosis of HTLV-I-infected patients
as well as a target of drug development to treat advanced
ATL patients.
In conclusion, our results show that TBP-2 plays an important
role in mediating GC-induced cell death in HTLV-I-infected
T-cell lines. Our results also raise the therapeutic prospect of
inducing TBP-2 expression in improving the efﬁcacy of the
current GC-based chemotherapy.
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